Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASGR1 | P07306 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17586288 | 0.87 | HDAC6 (0.32) | ASGR1HDAC1HDAC2HDAC6 | |
| SCHEMBL17582445 | 0.85 | ASGR1 (0.33) | ASGR1 | |
| SCHEMBL17586292 | 0.82 | ASGR1 (0.32) | ASGR1HDAC1HDAC2HDAC6 | |
| SCHEMBL23284466 | 0.81 | ASGR1 (0.31) | ASGR1HDAC1HDAC2HDAC6 | |
| SCHEMBL30885816 | 0.79 | ASGR1 (0.31) | ASGR1HDAC1HDAC2HDAC6 | |
| SCHEMBL18038888 | 0.79 | ASGR1 (0.31) | ASGR1HDAC1HDAC2HDAC6 | |
| SCHEMBL24462299 | 0.79 | ASGR1 (0.31) | ASGR1HDAC1HDAC2HDAC6 | |
| SCHEMBL20848346 | 0.78 | ASGR1 (0.38) | ASGR1HDAC1HDAC2HDAC6 | |
| SCHEMBL17586268 | 0.78 | OPRM1 (0.32) | — | |
| SCHEMBL20848339 | 0.77 | DGAT1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975035-B2 | Bicyclic compounds | RECURIUM IP HOLDINGS, LLC (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190233377-A1 | BICYCLIC COMPOUNDS | Zeno Royalties & Milestones, LLC | 2019-08-01 | — | — | US | disclosed |
| US-10308609-B2 | Bicyclic compounds | Zeno Royalties & Milestones, LLC (US) | 2019-06-04 | — | — | US | disclosed |
| US-20160075654-A1 | BICYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233377-A1 | BICYCLIC COMPOUNDS | OPRK1, OPRM1, OPRL1 | ASGR1 4577/4885HDAC1 486/4885HDAC2 487/4885 |
| US-20160075654-A1 | BICYCLIC COMPOUNDS | OPRK1, OPRM1, OPRL1 | ASGR1 4577/4885HDAC1 486/4885HDAC2 487/4885 |
| US-10975035-B2 | Bicyclic compounds | OPRK1, OPRM1, OPRL1 | ASGR1 4577/4885HDAC1 486/4885HDAC2 487/4885 |
| US-10308609-B2 | Bicyclic compounds | OPRK1, OPRM1, OPRL1 | ASGR1 4577/4885HDAC1 486/4885HDAC2 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.